A systematic review and meta-analysis of the gonadotoxic effects of cyclophosphamide and benefits of gonadotropin releasing hormone agonists (GnRHa) in women of child-bearing age with autoimmune rheumatic disease.

Conclusion: Sustained amenorrhoea with IV cyclophosphamide was observed in patients with ARD, especially with increasing age and cumulative doses >5g. GnRHa reduced this risk and should be considered with IV cyclophosphamide in women of childbearing age with ARD. PMID: 32005081 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32005081?dopt=Abstract

Source: Expert Review of Clinical Immunology - February 2, 2020 Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research